参考文献/References:
[1] Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk sqimmous-cell carcinoma of the head and neck. N Engl J Med, 2004, 350(19):1937-1944.
[2] Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med, 2004, 350(19):1945-1952.
[3] Zhukov NV, Tjulandin SA. Targeted therapy in the treatment of solid tumors:practice contradicts theory. Biochemistry (Mosc),2008,73(5):605-618.
[4] Longley DB, Harkin DP, Johnston PG. 5-fluorouracil:mechanisms of action and clinical strategies. Nat Rev Cancer, 2003,3(5):330-338.
[5] Spalding AC, Lawrence TS. New and emerging radiosensitizers and radioprotectors. Cancer Invest, 2006,24(4):444-456.
[6] Morgan MA, Parsels LA, Maybaum J, et al. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy:a review. Clin Cancer Res, 2008, 14(21):6744-6750.
[7] Morgan MA, Parsels LA, Parsels JD, et al. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res, 2005, 65(15):6835-6842.
[8] Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother, 2005, 6(1):85-92.
[9] Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways:validated targets for cancer treatment. Drugs, 2007, 67(14):2045-2075.
[10] Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality?. Nat Rev Clin Oncol, 2010,7(7):401-414.
[11] Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs, 2010, 19(9):1049-1066.
[12] Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma:the Pelvic Radiation and Vorinostat (PRAVO)phase 1 study. Lancet Oncol, 2010, 11(5):459-464.
[13] Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the National Institutes of Health:HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med, 2011, 15(12):2735-2744.
[14] Chen X,Wong P, Radany EH, et al. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res,2012,10(8):1052-1064.
[15] Kim KW, Mutter RW, Cao C, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther, 2006,5(11):2659-2665.
[16] Johnson GE, Ivanov VN, Hei TK. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis, 2008, 13(6):790-802.
[17] Chen J,Wang J,Lin L,et al. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther, 2012, 11(2):277-287.
[18] L?ser DA, Shibata A, Shibata AK, et al. Sensitization to radiation and alkylating agents by inhibitors of poly (ADP-ribose)polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther, 2010, 9(6):1775-1787.
[19] Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005,434(7035):917-921.
[20] Chalmers AJ, Lakshman M, Chan N, et al. Poly (ADP-ribose)poly-merase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol, 2010, 20(4):274-281.
[21] Che SM, Zhang XZ, Hou L, et al. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Invest, 2010, 28(7):679-688.
[22] Che SM, Zhang XZ, Liu XL, et al. The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells. Dis Esophagus, 2011,24(4):265-273.
[23] Dittmann KH, Mayer C,Ohneseit PA, et al. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair:a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys, 2008, 70(1):203-212.
[24] Grimes KR, Warren GW, Fang F, et al. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep, 2006,16(4):771-776.
[25] Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials:the cross trial safety analysis. Circulation, 2008, 117(16):2104-2113.
[26] Cerella C, Sobolewski C, Dicato M, et al. Targeting COX-2 expression by natural compounds:a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem Pharmacol, 2010, 80(12):1801-1815.
[27] H?rdtner C, Multhoff G, Falk W, et al. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol, 2012, 684(1-3):36-43.
[28] Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal, 2005,7(11-12):1630-1647.
[29] Nambiar D, Rajamani P, Singh RP. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat Res, 2011,728(3):139-157.
[30] Qiao Q, Jiang Y, Li G. Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-кB pathway:an in-vitro study of lymphoma. Anticancer Drugs, 2012,23(6):597-605.
[31] Veeraraghavan J, Natarajan M, Lagisetty P, et al. Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells. Pancreas, 2011,40(7):1107-1119.
[32] Liu J, Zhang J, Wang X, et al. HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res, 2010,316(12):1985-1993.
[33] Moon SY, Chang HW, Roh JL, et al. Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral oncol, 2009, 45(10):915-919.
[34] Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer, 2009,100(5):747-757.
[35] Lee K, Zhang H, Qian DZ, et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA,2009,106(42):17910-17915.
[36] Kim WY, Oh SH, Woo JK, et al. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res, 2009, 69(4):1624-1632.
[37] Semenza GL. Hypoxia-inducible factor 1(HIF-1) pathway. Sci STKE, 2007, 2007(407):cm8.
[38] Singh-Gupta V,Zhang H, Banerjee S,et al. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer, 2009, 124(7):1675-1684.
[39] Shi M, Guo XT, Shu MG, et al. Cell-permeable hypoxia-inducible factor-1(HIF-1)antagonists function as tumor radiosensitizers. Med Hypotheses, 2007, 69(1):33-35.
[40] Yang CM, Lee IT, Lin CC, et al. Cigarette smoke extract induces COX-2 expression via a PKCalpha/c-Src/EGFR, PDGFR/PI3K/Akt/NF-kappaB pathway and p300 in tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2009,297(5):L892-902.
[41] Cheng JC, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene, 2006, 25(53):7009-7018.
[42] Rudner J,Huiner CE, Handrick R, et al. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol, 2010,5:108.
[43] Kao GD, Jiang Z, Fernandes AM, et al. Inhibition of phosphatidyli-nositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem, 2007, 282(29):21206-21212.
[44] Chendil D, Ranga RS, Meigooni D, et al. Curcumin confers radio-sensitizing effect in prostate cancer cell line PC-3. Oncogene, 2004, 23(8):1599-1607.
[45] Sandur SK, Deorukhkar A, Pandey MK, et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys, 2009, 75(2):534-542.
[46] Sung B, Pandey MK, Ahn KS, et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappa Balpha kinase,leading to potentiation of apoptosis. Blood, 2008, 111(10):4880-4891.
[47] Zand H, Rahimipour A, Salimi S, et al. Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem, 2008,317(1-2):113-120.
[48] Wang L, Fu JN, Wang JY, et al. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy. Anticancer Drugs, 2011, 22(8):732-740.
[49] Taba K, Kuramitsu Y, Ryozawa S, et al. KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy, 2011,57(1):12-16.
[50] Sahin E,Sahin M,Sanlio?lu AD, et al. KNK437, a benzylidene lactam compound, sensitises prostate cancer cells to the apoptotic effect of hyperthermia. Int J Hyperthermia, 2011, 27(1):63-73.
[51] Hickson I,Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiec-tasia mutated kinase ATM. Cancer Res, 2004, 64(24):9152-9159.
[52] Won J, Kim M, Kim N, et al. Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol, 2006, 2(7):369-374.
[53] Rainey MD, Charlton ME, Stanton RV, et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res, 2008,68(18):7466-7474.
[54] Tofilon PJ, Camphausen K. Molecular targets for tumor radiosensitization. Chem Rev, 2009, 109(7):2974-2988.
[55] 王浩,周晓靓,施培基,等. 靶向放射增敏剂的研究进展. 中华放射医学与防护杂志,2011,31(2):243-245.
相似文献/References:
[1]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[2]刘晓秋,周则卫,沈秀,等.放射增敏剂尼可胺对Wistar大鼠致畸作用的研究[J].国际放射医学核医学杂志,2013,37(2):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
LIU Xiao-qiu,ZHOU Ze-wei,SHEN Xiu,et al.Study on teratogenicity of Nikean in Wistar rats[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):81.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
[3]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[4]刘晓秋,沈秀,王芹,等.尼可胺在大鼠体内的药代动力学研究[J].国际放射医学核医学杂志,2013,37(5):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
LIU Xiao-qiu,SHEN Xiu,WANG Qin,et al.Study on pharmacokinetics of NiKeAn in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
[5]龙伟,吴红英,张晓东,等.血必净辐射防护作用机制的计算机模拟研究[J].国际放射医学核医学杂志,2013,37(6):329.[doi:10.3760/cma.j.issn.1673-4114.2013.06.001]
LONG Wei,WU Hong-ying,ZHANG Xiao-dong,et al.Computational study for mechanisms of radiation protection effects of Xuebijing[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):329.[doi:10.3760/cma.j.issn.1673-4114.2013.06.001]
[6]李玉,董丹,阎英.肿瘤辐射增敏机制研究进展[J].国际放射医学核医学杂志,2007,31(1):48.
LI Yu,DONG Dan,Yah Ying.The development of radiosensitizer mechanisms[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):48.
[7]顾菲,刘晓秋.肿瘤辐射增敏的分子机制[J].国际放射医学核医学杂志,2006,30(5):298.
GU Fei,LIU Xiao-qiu.The molecular mechanism of tumor radiosensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):298.
[8]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
[9]董正川,段玉清,樊赛军,等.新型辐射增敏药RRx-001[J].国际放射医学核医学杂志,2017,41(3):214.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
Dong Zhengchuan,Duan YuQing,Fan Saijun,et al.A novel radiosensitizer RRx-001[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):214.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]